IU Health and the Indiana University Melvin and Bren Simon Comprehensive Cancer Center plans to develop a state-wide mobile lung cancer screening program as a result of a $4.5 million gift from The Tom and Julie Wood Family Foundation, which includes $4 million matching dollars from Indiana University Health.
Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.
